By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MDxHealth said today that Celldex Therapeutics will use its epigenetic MGMT test during recruitment of patients for a Phase III clinical study of Celldex's immunotherapeutic vaccine, rindopepimut, in newly diagnosed glioblastoma multiforme.

The study is expected to recruit 374 patients with newly diagnosed EGFRvIII-expressing GBM, an aggressive form of brain cancer, following gross total resection at more than 150 global clinical sites.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.